Guangdong Jiaying Pharmaceutical Co., Ltd
Symbol: 002198.SZ
SHZ
6.73
CNYTržní cena dnes
121.8232
Poměr P/E
10.9641
Poměr PEG
3.42B
MRK Cap
- 0.00%
Výnos DIV
Guangdong Jiaying Pharmaceutical Co., Ltd (002198-SZ) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1231.73 | 334 | 234.1 | 239.4 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 660.9 | 200.5 | 50.3 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 657.68 | 154 | 240.6 | 175.7 | ||||||||||||||||||||
balance-sheet.row.inventory | 347.58 | 84.6 | 82.3 | 73.4 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 5.96 | 1.1 | 0.4 | 1.2 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 2267.86 | 580.2 | 557.4 | 489.7 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 769.11 | 190.4 | 203.7 | 224.2 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 191.46 | 47.2 | 52.4 | 58.3 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 191.46 | 47.2 | 52.4 | 58.3 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | -134.09 | 27.1 | -20.9 | 30.6 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 8.72 | 2.2 | 2.2 | 4.6 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 240.92 | 0.5 | 51.8 | 0 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 1076.11 | 267.4 | 289.2 | 317.7 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 3343.97 | 847.6 | 846.7 | 807.3 | ||||||||||||||||||||
balance-sheet.row.account-payables | 42.13 | 9.2 | 19 | 14.1 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | -2.03 | 0 | 5.8 | 31.1 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 28.03 | 7.5 | 17.2 | 12 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||||
Deferred Revenue Non Current | 1.72 | 0.4 | 0.5 | 0.2 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 139.12 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 118.62 | 40.2 | 47.1 | 5.7 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 140.84 | 35.2 | 35.3 | 34.9 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-liab | 315.92 | 84.6 | 118.2 | 122.9 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 54.45 | 27.2 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 2030.04 | 507.5 | 507.5 | 507.5 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 398.09 | 104.6 | 70.3 | 26.3 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 174.76 | 0 | 27.2 | 27.2 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 370.71 | 123.7 | 123.4 | 123.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 3028.05 | 763 | 728.4 | 684.5 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3343.97 | 847.6 | 846.7 | 807.3 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 3028.05 | 763 | 728.4 | 684.5 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3343.97 | - | - | - | ||||||||||||||||||||
Total Investments | 105.91 | 27.1 | 29.4 | 30.6 | ||||||||||||||||||||
balance-sheet.row.total-debt | 5.87 | 0 | 5.8 | 31.1 | ||||||||||||||||||||
balance-sheet.row.net-debt | -564.95 | -133.5 | -178.1 | -208.3 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 27.32 | 43.9 | 1.5 | 19.8 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 18.01 | 25.9 | 28.4 | 28.2 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 2.4 | 1 | -0.6 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -2.4 | -1 | 0.6 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 116.01 | -48.4 | -4.8 | 38.8 | |||||||||||||||||||
cash-flows.row.account-receivables | 118.37 | -86.5 | 9.6 | 9 | |||||||||||||||||||
cash-flows.row.inventory | -2.36 | -8.4 | -0.8 | 2.5 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | 44.1 | -14.7 | 27.9 | |||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 2.4 | 1 | -0.6 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -48.06 | 5.7 | 26.7 | 10 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 113.28 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -12.26 | -2.7 | -2.3 | -11.7 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 141.97 | 0.1 | 0 | 0 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -0.1 | 0 | 0 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | -126.83 | 1.6 | 32.5 | 18.5 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -180 | -49.9 | 25.1 | -25 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -176.93 | -51 | 55.2 | -18.2 | |||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -31.1 | -15 | -135 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -0.5 | -1 | -3.8 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 31.1 | 55 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -31.6 | 15.1 | -83.8 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | -64.89 | -55.4 | 122.1 | -5.1 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 567.95 | 183.9 | 239.3 | 117.2 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 632.85 | 239.3 | 117.2 | 122.3 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 113.28 | 27.2 | 51.8 | 96.9 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -12.26 | -2.7 | -2.3 | -11.7 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 101.02 | 24.4 | 49.5 | 85.2 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 499.15 | 533.2 | 659.2 | 574.7 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 184.54 | 185.5 | 228.5 | 141.9 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 314.61 | 347.7 | 430.7 | 432.8 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 10.47 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 13.37 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 219.49 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | -1.19 | -1.1 | 40.7 | 46.3 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 285.61 | 310.4 | 376 | 403.2 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 470.15 | 495.9 | 604.5 | 545.1 | ||||||||||||||||||||
income-statement-row.row.interest-income | 2.17 | 2.1 | 2.3 | 2.6 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0.5 | 1 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 219.49 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0.14 | 2.1 | -2.8 | -27.8 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -1.19 | -1.1 | 40.7 | 46.3 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0.14 | 2.1 | -2.8 | -27.8 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0.5 | 1 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 8.91 | 24.2 | 26.6 | 28.4 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 30.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 33.65 | 40.5 | 53.9 | 33.6 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 32.46 | 39.4 | 51.1 | 5.8 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 5.15 | 5.1 | 7.2 | 4.3 | ||||||||||||||||||||
income-statement-row.row.net-income | 27.32 | 34.3 | 43.9 | 1.5 |
Často kladené otázky
Co je Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) celková aktiva?
Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) celková aktiva jsou 847563113.000.
Jaký je roční obrat podniku?
Roční příjmy jsou 250417163.000.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.630.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je 0.199.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.055.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.067.
Co je Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 34320234.000.
Jaký je celkový dluh podniku?
Celkový dluh je 0.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 310409681.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 118503980.000.